Immune Design Presents Data on the Mechanism of Action of G100 via TLR4 Expressed in B Cell Malignancies at the Inaugural AACR International Meeting Advances in Malignant Lymphoma
25 juin 2018 08h00 HE
|
Immune Design Corp.
- G100 directly targets and modifies TLR4 expressing malignant B cells making them more visible to the anti-tumor immune response- SEATTLE and SOUTH SAN FRANCISCO, Calif., June 25, 2018 (GLOBE...
Immune Design to Host June 4 Cancer Immunotherapy Event in Chicago and Present at Jefferies 2018 Global Healthcare Conference in New York
01 juin 2018 08h00 HE
|
Immune Design Corp.
SEATTLE and SOUTH SAN FRANCISCO, Calif., June 01, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), an immunotherapy company focused on novel therapies in oncology, today announced that the...
Immune Design Announces Launch of Web Portal for SYNOVATE Phase 3 Study of CMB305 Immunotherapy in Synovial Sarcoma
24 mai 2018 08h00 HE
|
Immune Design Corp.
-- 1st global Phase 3 trial focused on synovial sarcoma patients -- www.synovatestudy.com SEATTLE and SOUTH SAN FRANCISCO, Calif., May 24, 2018 (GLOBE NEWSWIRE) -- Immune...
Immune Design Reports First Quarter 2018 Financial Results and Provides Corporate Update
02 mai 2018 16h01 HE
|
Immune Design Corp.
The higher dose of CMB305 was deemed safe and cleared for the pivotal Phase 3The 20ug dose of G100 shows a two-fold increase in TILs, higher than that seen at the 10ug doseConference call at 1:30 pm...
Immune Design to Report First Quarter 2018 Financial Results and Provide Corporate Update
25 avr. 2018 08h00 HE
|
Immune Design Corp.
SEATTLE and SOUTH SAN FRANCISCO, Calif., April 25, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today announced...
Immune Design Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update
14 mars 2018 16h01 HE
|
Immune Design Corp.
- New positive clinical and translational data for both lead agents - Strong balance sheet with 2017 year-end cash and equivalents of $144.2 Million - Conference call at 1:30 pm Pacific today ...
Immune Design Reports Data Update for Lead Immunotherapy Programs: Improvement in Survival for CMB305 Monotherapy in Sarcoma and Increased Objective Responses for G100/pembrolizumab Combination in Follicular Lymphoma
12 mars 2018 08h00 HE
|
Immune Design Corp.
Median overall survival of 23.7 months following CMB305 monotherapy represents approximately one-year extension of survival compared to published data in soft tissue sarcoma patient...
Immune Design to Report Fourth Quarter and Year End 2017 Financial Results and Provide Corporate Update
07 mars 2018 08h00 HE
|
Immune Design Corp.
SEATTLE and SOUTH SAN FRANCISCO, Calif., March 07, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today announced...
Immune Design to Present at Upcoming Investor Conferences
09 févr. 2018 08h00 HE
|
Immune Design Corp.
SEATTLE and SOUTH SAN FRANCISCO, Calif., Feb. 09, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today announced...
Combination of G100 with KEYTRUDA (pembrolizumab) Triggers Robust Systemic Responses in Follicular NHL Patients
10 déc. 2017 09h00 HE
|
Immune Design Corp.
39% ORR for G100+pembrolizumab is greater than either agent alone; reaches 57% ORR in the TLR4high patient population receiving G100+pembrolizumab (potential predictive biomarker)Responses occur in...